drugset / Trial / NCT05236998

A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

NCT05236998

Phase 1 Completed 45 enrolled SK Chemicals Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.

Timeline

Start
2021-11-03
Primary completion
2021-12-21
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule Oral
Subject SID1903 Unknown Oral
Subject Sitagliptin Small molecule Oral

Indications

No indication recorded.